April, 2025
April 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
282930  
Ruben Mesa: Pelabresib plus Ruxolitinib for JAKi naive Myelofibrosis
Mar 12, 2025, 10:16

Ruben Mesa: Pelabresib plus Ruxolitinib for JAKi naive Myelofibrosis

Ruben Mesa, President and Executive Director of Atrium Health Levine Cancer Institute and Atrium Health Wake Forest Baptist Comprehensive Cancer Center, shared an article by Raajit K. Rampal, et al. on LinkedIn:

“Honored to have joined many wonderful colleagues in these important PhaseIII trial data for combination Pelabresib plus Ruxolitinib for JAKi naive myelofibrosis.”

Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial.

Authors: Raajit K. Rampal, et al.

Ruben Mesa: Pelabresib plus Ruxolitinib for JAKi naive Myelofibrosis